June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Refractive Error in Inherited Retinal Disease: A review of Findings from Three Academic Centers.
Author Affiliations & Notes
  • Shaden Yassin
    University of California at San Diego Department of Ophthalmology at the Shiley Eye Institute, La Jolla, California, United States
  • Thomas Khuu
    Oregon Health & Science University Casey Eye Institute, Portland, Oregon, United States
  • Ryan Schmidt
    Oregon Health & Science University Casey Eye Institute, Portland, Oregon, United States
  • Austin Igelman
    Oregon Health & Science University Casey Eye Institute, Portland, Oregon, United States
  • Molly Marra
    Oregon Health & Science University Casey Eye Institute, Portland, Oregon, United States
  • Hillary Schwartz
    Children's Hospital Los Angeles, Los Angeles, California, United States
  • Evan Walker
    University of California at San Diego Department of Ophthalmology at the Shiley Eye Institute, La Jolla, California, United States
  • Aaron Nagiel
    Children's Hospital Los Angeles, Los Angeles, California, United States
    University of Southern California, Los Angeles, California, United States
  • Mark E Pennesi
    Oregon Health & Science University Casey Eye Institute, Portland, Oregon, United States
  • Shyamanga Borooah
    University of California at San Diego Department of Ophthalmology at the Shiley Eye Institute, La Jolla, California, United States
  • Footnotes
    Commercial Relationships   Shaden Yassin None; Thomas Khuu None; Ryan Schmidt None; Austin Igelman None; Molly Marra None; Hillary Schwartz None; Evan Walker grant P30EY022589, Code R (Recipient); Aaron Nagiel Lexitas, Eyebiotech, Biogen, Novartis, Atsena, Janssen, Code C (Consultant/Contractor); Mark Pennesi 4D Molecular Therapeutics, Abbvie, Adverum, AGTC, Aldebaran, Alnylam, Ascidian, Atsena, Astellas, Bayer, Biogen, BlueRock-Opsis, ClarisBio, DTx Therapeutics, Editas, Endogena, Eyevensys, Foundation Fighting Blindness, Intergalactic Therapeutics, IVERIC, Janssen, Mogrify, Nacuity Pharmaceuticals, Novartis, Ocugen, ProQR, Prime Editing, PYC Therapeutics, Rejuvitas, RestoreVision, RegenexBio, Roche, Sanofi, Saliogen, Sparing Vision, TwentyTwenty, Thea, Viewpoint Therapeutics, Vedere, , Code C (Consultant/Contractor), Sanofi, ProQR, Foundation Fighting Blindness, Editas, Biogen, AGTC, , Code F (Financial Support), Atsena, DTx Therapeutics, Nacuity Pharmaceuticals, Ocugen, Vedere, Sparing Vision, Eyevensys, , Code R (Recipient); Shyamanga Borooah Foundation Fighting Blindness, Nixon Vision Award, Code R (Recipient)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 4637. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Shaden Yassin, Thomas Khuu, Ryan Schmidt, Austin Igelman, Molly Marra, Hillary Schwartz, Evan Walker, Aaron Nagiel, Mark E Pennesi, Shyamanga Borooah; Refractive Error in Inherited Retinal Disease: A review of Findings from Three Academic Centers.. Invest. Ophthalmol. Vis. Sci. 2023;64(8):4637.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The prevalence of ametropia in inherited retinal dystrophies (IRDs) and its genetic associations is poorly studied. We aim to address this knowledge gap by performing a retrospective cross-sectional study of ametropia in a cohort of IRD patients reviewed at three academic ophthalmology referral centers.

Methods : Cases were included from the dystrophy clinics of the Shiley Eye Institute, University of California San Diego, Casey Eye Institute, Oregon Health and Science University and Children Hospital of Los Angeles. Patients were included with clinically and molecularly confirmed IRD. Data reviewed included age, gender, disease phenotype and genotype, best corrected visual acuity, objective, and subjective refraction. Distributions and mean spherical equivalent (SE) were calculated for causal genes. The Analysis of SE was conducted through Linear Mixed Effects modeling, with a random intercept to account for intercorrelated subject eyes. Statistical analyses were performed using the R statistical software (R Version 4.2.2).

Results : In total 768 patients were included, 412 (54%) were males, mean age was 34.9 years (33.4, 36.4). Of these, 669 patients (1307 eyes) had refractive data, 388 patients (58%) (696 eyes, 53%) were ametropic (Fig. 1). Investigating genes associated with myopia (Fig. 2), RP1 (n=34, 2.2%) had the highest odds ratio of myopia (3.466, P=0.002; SD=2.4); followed by RPGR (n=104, 6.8%)(1.933, P=0.006; SD=4.47); and ABCA4 (n= 150, 9.8%)(1.494, P=0.05; SD=2.36). For genes associated with hyperopia (Fig.2), CRB1 (n= 22, 1.4%) had the highest odds ratio of hyperopia (8.678 P<0.001; SD=4.1); followed by BEST1 (n= 46, 3%)(8.172, P<0.001; SD=3.15); and RS1 (n= 26, 1.7%)(6.539, P<0.001; SD=2.62). n=number of eyes, 2 eyes per subject was used for SE analysis when available.

Conclusions : Ametropia was commonly seen in IRD patients. The pattern of error of refraction varied widely by causal gene. Our findings confirm previous reports that some genes, such as RP1 were associated with myopia, as well as other genes such as CRB1 were associated with hypermetropia. However, the genes identified require further validation in larger cohorts and are candidates for more in-depth investigation in functional studies of refractive error.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

 

Figure 1: Overall prevalence of Ametropia.

Figure 1: Overall prevalence of Ametropia.

 

Figure 2: Box plot of Mean SER by Causal Gene

Figure 2: Box plot of Mean SER by Causal Gene

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×